Drug Profile

Latanoprost - Laboratoires Thea

Alternative Names: IYUZEH; LUDPF; Monopost; Monoprost; Non-preserved latanoprost - Laboratoires Thea

Latest Information Update: 28 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Laboratoires Thea
Developer Clermont Pharmaceuticals; Laboratoires Thea
Class Antiglaucomas; Eye disorder therapies; Prostaglandins; Small molecules
Mechanism of Action Prostaglandin F2 alpha agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Glaucoma; Ocular hypertension

Most Recent Events

26 Sep 2023 Launched for Glaucoma in USA (Ophthalmic)
26 Sep 2023 Launched for Ocular hypertension in USA (Ophthalmic)
03 Mar 2023 Thea Pharma announces intention to launch Latanoprost (IYUZEH™) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension in USA in second half of 2023

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com